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Background: A primary concern in the use of EBP in these patients is the possibility of seeding 
the virus in the CNS. Another important concern is related to the known hypercoagulable state 
in COVID-19 positive patients and associated organ dysfunction that may alter the metabolism 
of anticoagulants. The safety of the providers performing the EBP, the position of the patient and 
choices for image guidance (blind, fluoroscopic) are also key considerations to review. It is also 
important to explore the current state of knowledge about using allogenic instead of autologous 
blood as well as emerging techniques to eliminate the coronavirus from the blood.
Objectives: In this article we pose the questions of how to manage PDPH in the COVID-19 
positive patient and more specifically, the use of epidural blood patch (EBP).
Methods: Literature review.
Results: EBP is usually considered after the failure of conservative and pharmacological 
treatments. Because of the additional risks of EBP in COVID-19 patients it is important to also 
consider less traditional pharmacological treatments such as theophylinnes and cosyntropin that 
may offer some additional benefit for COVID-19 patient.  Finally, other interventions other than 
EBP should also be considered including occipital nerve blocks, sphenopalatine ganglion blocks 
(infratemporal or transnasal).
Limitations: A narrative review with paucity of literature.
Conclusion: Going forward, an effective treatment for COVID-19 or a safe vaccine and a deeper 
understanding of the pathophysiology of the virus will certainly change the risk calculus involved 
in performing an EBP in a COVID-19 patient.
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In this new age of coronavirus disease 2019 (COVID-19) and during the early phase of the pandemic, much of the focus has been on the acute 
critical care of the COVID-19 patient. Going forward, 
the management of certain medical conditions in this 
patient population will also need to be addressed, as it 
presents several challenges. In this article, we discuss the 
treatment approach of postdural puncture headache in 
the COVID-19 patient and more specifically, the use of 
an epidural blood patch (EBP).   
Postdural puncture headache (PDPH) is a rare but 
known complication after an epidural procedure or 
lumbar puncture. While in severe cases it can cause cere-
bral herniation and brain death if not treated promptly, 
in most cases it is not a life-threatening condition, but 
can be associated with severe and acute suffering as well 
as temporary but significant functional impairment. 
One of the most common and effective procedures in 
the treatment of PDPH is an EBP. The success rate for 
this procedure continues to be as high as 93% after the 
first attempt and 97% on the second attempt, with few 
complications (1). 
COVID-19 is a novel coronavirus that has resulted 
in significant worldwide morbidity and mortality. It has 
Pain Physician: August 2020 COVID-19 Special Issue 23:S305-S310
S306  www.painphysicianjournal.com
affecting the blood brain barrier via ACE2 receptors, 
and the sequelae of acute thromboembolic events (4-
6). It also remains unclear whether CNS symptoms are 
a reflection of CSF viral load. There have been cases of 
COVID-positive patients with Guillain-Barre syndrome 
and CSF-negative SARS-CoV-2 polymerase chain reac-
tion (PCR) assays, as well as patients with symptoms of 
meningitis found to have CSF-positive SARS-CoV-2 PCR 
assays and negative nasopharyngeal swabs (5-7).  
These concerns lead us to question the appropri-
ateness of our current practice of injecting autologous 
blood in COVID-19 patients who may or may not have 
CNS manifestations.  Should we be assaying CSF involve-
ment for the presence of SARS-CoV-2 prior to an EBP 
and potential introduction of virus into the CNS? An-
swers to these questions may become clear as we learn 
more about the COVID-19 virus and its pathophysiology. 
It is worthwhile to note that there have been numer-
ous articles reviewing specific patient populations and 
implying that the risk of a new CNS infection related to 
a neuraxial procedure or intervention, while possible, 
is extremely low, ranging from 0.007% to 0.6% with 
ongoing bacteremia (8,9). In patients with documented 
bacteremia, such as chorioamnionitis, there were no 
patients who developed CNS infection after neuraxial 
procedures (10-12). Review of patients with known or 
highly suspected orthopedic localized joint infections 
and neuraxial anesthesia likewise did not report any 
new neuraxial infectious process (8,9). In patients with 
HIV, a blood patch after dural tap does not predispose 
for neurological disease progression (13). Similarly, active 
herpetic lesions did not lead to infectious complications 
following neuraxial anesthetic techniques in the obstet-
ric population (14,15). So, in general, these findings sug-
gest an extremely low risk of transferring a blood-borne 
pathogen in the CNS when performing an EBP using 
autologous blood for a patient with an ongoing infec-
tion. Others have suggested that central neuraxial blocks 
should not be performed in patients with untreated sys-
temic infections, but that patients may safely undergo 
spinal anesthesia if prior antibiotic therapy has been 
initiated (16). Since there is no gold standard treatment 
for COVID-19 at this time and since there are still many 
unknowns about this virus, these findings may not be 
applicable to COVID-19-positive patients. 
Can allogeniC Blood Be Used for Blood 
PatCh?
To alleviate the concern of injecting autologous 
blood during active infection that likely contains viral 
become increasingly common in the community, and 
yet can remain asymptomatic in as many as 80% of pre-
senting patients. These patients are part of the general 
population that may also be receiving spinal procedures 
such as labor epidurals, surgical anesthesia, and proce-
dures for pain management. In addition, patients may 
undergo lumbar punctures as a diagnostic tool to aid in 
treatment, planning, and administration of therapeu-
tics such as chemotherapy or in the urgent diagnosis 
of increased intracranial pressure. Furthermore, there 
have been recommendations from multiple medical 
societies to maximize the use of regional and neuraxial 
anesthesia for COVID-19-positive patients in the peri-
operative period (2). This is hypothesized to reduce the 
risk of aerosolization of viral particles associated with 
the airway manipulation that occurs with general anes-
thesia (3). As a result, it is reasonable to expect a higher 
use of neuraxial anesthesia for COVID-19-positive pa-
tients in the months to come. Inevitably, a percentage 
of these patients may develop complications such as a 
PDPH – requiring the utilization of an EBP to manage 
their symptoms. When treating COVID-19 patients with 
an EBP for PDPH, a significant concern is the potential 
seeding of virus into the central nervous system (CNS). 
The sequelae of such seeding in the CNS, especially in 
patients who have no or mild COVID-related symptoms, 
could be devastating.  
This article discusses the risks of transmission of the 
virus to the CNS while performing an EBP on COVID-
19-positive patients, leading to possible neurological 
sequelae as well as options to process the blood to 
decrease this risk of transmission. Other considerations 
specific to COVID-19 patients, such as coagulation sta-
tus and protection of the care team performing an EBP, 
will also be highlighted. Finally, we will review both 
pharmacological and interventional alternatives to an 
EBP for the treatment of PDPH and their use in the 
treatment of PDPH in COVID-19 patients. 
CoVid-19 and the Central nerVoUs 
system
While literature on COVID-19 is evolving daily, 
the spread of this virus within the CNS, including ce-
rebrospinal fluid (CSF) and the epidural space, has yet 
to be fully understood. There are known CNS-related 
COVID-19 manifestations such as anosmia, ageusia, 
confusion, altered mental status, encephalitis, and 
meningitis. These may be attributable to factors includ-
ing direct infection, injury, neuronal pathway disrup-
tion, acute cerebrovascular disease, vascular changes 
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particles, it may be worthwhile to examine the use of 
allogenic blood from appropriately matched donors. In 
one case report (17), a woman with intractable PDPH 
and fever received an EBP with crossmatched blood that 
was screened for infectious diseases. The patient went 
on to have complete resolution of her headache and 
remained symptom-free after a one-month follow-up. 
Although no studies have demonstrated a direct causal 
relationship between meningitis and dural puncture in 
the presence of infection, the authors concluded that 
it is appropriate to use crossmatched and tested blood, 
as long as it is conducted under aseptic conditions (17). 
While this approach certainly requires further investiga-
tion and should only be reserved for patients who exhibit 
no response to conventional therapy, it does address the 
concern of directly introducing COVID-19 into the CNS. 
Can Blood Be disinfeCted?
Another consideration for novel and nonconven-
tional therapy is the use of ultraviolet light for disinfec-
tion of blood prior to injection into the epidural space. 
The idea of using ultraviolet radiation in the treatment 
of bacterial and viral infection was introduced more 
than a century ago (18). Ultraviolet blood irradiation 
(UVBI) works by enhancing the body’s natural immune 
response as well as being directly lethal to viral and 
bacterial pathogens. During this process, a needle is in-
serted into a vein and 60 or more milliliters of blood are 
passed through tubing where it is exposed to an ultra-
violet light. The treated blood is then directly returned 
to the patient’s bloodstream. In a study looking at the 
treatment of patients with hepatitis C infection, UVBI 
was both safe and effective in reduction of viral load 
and improvement of symptoms (18). If there is a similar 
effect on COVID-19-infected blood, this therapy may 
prove to be a reasonable and safe option in cases of 
active infection and debilitating PDPH. However, at this 
time, there is little data to support its use and further 
investigation is certainly needed.
One future consideration for safe blood admin-
istration in patients might be the ExThera Seraph®100 
Microbind® Affinity Blood Filter - a hemoperfusion device 
for the reduction of pathogens and reduction of viral 
load in filtered blood. Although used in Europe, it has 
not yet been approved in the United States (19). 
CoagUlation Considerations
Another significant concern relates to the known 
hypercoagulable state in patients with COVID-19, lead-
ing to thrombosis, venous and pulmonary thromboem-
bolism, stroke, and acute coronary syndromes. This is 
especially prevalent in patients with early elevation 
of d-dimers, c-reactive protein, and precalcitonin (20). 
These patients will often be treated with anticoagu-
lants such as unfractionated heparin, low-molecular 
weight heparin or direct oral anticoagulants. Prior to 
performing a blood patch in this population, the lab 
work and last dose of anticoagulation will need to be 
reviewed with greater vigilance. The risks of suspend-
ing anticoagulation for an EBP should be carefully 
weighed against the risks associated with a hyperco-
agulable state and when necessary, discussed with a 
hematologist. As with any patient exhibiting changes 
in their coagulation cascade, any procedure must be 
carefully considered with active hematologic changes 
in mind as a dynamic variable. 
Perhaps most important, prior to beginning the 
procedure, is determining the correct timing of the 
intervention. There are many articles that explore the 
best timing to perform spinal procedures safely, espe-
cially in challenging populations such as patients with 
coagulation issues (i.e., low platelets) or those who 
exhibit symptoms of a PDPH shortly after an epidural 
steroid injection (21,22). Anticoagulation guidelines for 
neuraxial anesthesia provide a possible easy road map 
assuming all anticoagulants work as expected in this 
new disease state. Possible concurrent organ dysfunc-
tion (kidneys in particular) should be considered while 
deciding on the timing of an EBP after discontinuation 
of anticoagulation.
has there Been an adeqUate trial of 
ConserVatiVe treatments?
It is important to keep in mind that PDPH is rarely 
an emergency unless intractable or associated with a 
severe CSF leak that causes traction on the epidural 
bridging veins. The most conservative approach for 
treating PDPH in COVID-19 patients is to wait for the 
resolution of active infection. As the sensitivity, speci-
ficity, and availability of COVID-19 testing continues 
to improve, this time period may be reduced. Since 
PDPH can result in significant morbidity, considering 
alternative treatments in COVID-19 patients may also 
be of great importance. Below is a review of the non-
interventional treatment options that are utilized with 
some success.  
noninterVentional treatment oPtions
In most cases of PDPH, there is a strong emphasis on 
conservative measures. The majority of cases resolve on 
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their own within days or weeks with minimal interven-
tion. However, episodes that are refractory to treatment 
can persist for months (23). In patients who do require 
an escalation of care, simple medications and treatment 
options are usually effective. Bedrest, caffeine, hydra-
tion, as well as acetaminophen and nonsteroidal anti-
inflammatory drugs are all useful in improving symp-
toms in many patients (24). Caffeine specifically has also 
shown benefit with breathing as it enhances inspiratory 
muscle endurance and reduces the workload on inspira-
tory muscles during respiration (25). Barbiturates such 
as butalbital and opioids can help with pain, but their 
use in patients with an active compromised respiratory 
status carries significant risk (25). Other options include 
theophyllines and adrenocorticotriopic hormone (ACTH) 
analogs, such as cosyntropin, as both have shown some 
efficacy in small studies (24). Theophylline has also shown 
some anti-inflammatory effect on the lungs and thus 
may be appropriate for COVID-19 patients (26). There is 
also evidence that part of the pathophysiology of the 
COVID-19 virus is to reduce the host’s cortisol response. 
This may occur due to viral production of amino acids 
that mimic ACTH, resulting in antibodies that attack 
ACTH (27). Clinical trials are underway examining the 
use of cortisol and ACTH in the treatment of COVID-19 
patients (28). To that effect, cosyntropin may offer some 
benefit in treating PDPH in this population. 
interVentional oPtions other than Blood 
PatCh
Several other interventions have been considered 
for the treatment of PDPH. One alternative investigat-
ed the use of epidural administration of various fluids 
or substances other than autologous blood. However, 
currently there is insufficient evidence to recommend 
the use of epidural crystalloids or other substances such 
as dextran, hydroethyl starch, or fibrin glue (24).
Additional interventions that have been studied 
include bilateral greater occipital nerve blocks (GON) 
and sphenopalatine ganglion blocks (SPG). Both have 
shown some efficacy in small studies, although there is 
a concern of aerosolization during transnasal spheno-
palatine ganglion block as the procedure may induce 
cough (24). For COVID-19 patients, a possible alterna-
tive is to use an ultrasound-guided infratemporal ap-
proach (29). 
risks to treatment team
Substantial consideration must also be given to 
how a blood patch can be performed with the greatest 
safety to the patient and care team. For instance, what 
should be the setup of the room? Where should every-
one stand in relation to the patient to mitigate viral 
spread? What is the best patient position, prone or sit-
ting, for the procedure and for the practitioner? There 
is evidence to support that patients with COVID-19 im-
prove respiratory mechanics in the prone position (30). 
Furthermore, a fluoroscopic approach may be prefer-
able as it has been shown to be more precise and associ-
ated with a higher success rate than a blind technique 
(31). Prone positioning may also offer greater distance 
for the care team from the patient’s face and may be 
more comfortable for the patient. A lateral recumbent 
position may also be an option to consider. Of course, 
complete personal protection including an N95 mask, 
face shield, gown, head cover, and sterile gloves need 
to be available and utilized. The patient should remain 
masked throughout the procedure. 
CliniCal reCommendations
In the decision-making algorithm to pursue inter-
ventional treatment for PDPH, an assessment of the 
risks and benefits must be considered by the patient 
and the care team with consideration of the patient’s 
clinical state and potential for complications. Although 
evidence for the EBP’s effectiveness remains the stron-
gest for the treatment of PDPH, initially a conservative 
approach using therapies such as hydration, bed rest, 
supine posture, caffeine, analgesics, theophylline, and 
cosyntropin is warranted for patients with an ongoing 
COVID-19 infection given the multitude of unknown 
implications for this patient population (26). 
If traditional pharmacological treatments have 
failed, are not available, or not indicated, consider bi-
lateral occipital nerve blocks (GON) or sphenopalatine 
ganglion blocks (SPG) using local anesthetics only. GON 
nerve blocks can be easily performed blindly or using 
ultrasound guidance and carry little risk of complica-
tions even for a patient on anticoagulation. While some 
of the authors have performed many transnasal sphe-
nopalatine ganglion blocks without inducing cough, it 
should be considered an aerosolization procedure and 
requires appropriate PPE. Alternatively, an infratempo-
ral ultrasound-guided approach could be used but is 
more technically challenging. If peripheral nerve blocks 
as listed above have failed, an EBP should be consid-
ered. Depending on the patient’s presentation and 
clinical condition, risk of viral contamination of the CSF 
or epidural space should be weighed against the ben-
efit of the EBP and the severity and impairment from 
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the PDPH. The prone position and use of fluoroscopic 
guidance may be beneficial both in terms of accuracy, 
speed of the procedure, patient comfort, and safety of 
the procedural team. 
limitations
One limitation of this review is that it is based 
on preliminary knowledge of COVID-19. There is little 
conclusive literature at this time on the rate, progres-
sion, and specific complications of COVID-19 spread in 
the CNS. Furthermore, the use of alternatives to EBP is 
based on small studies and often difficult to extrapo-
late to the general population. This topic also addresses 
a patient population that is difficult to study and in 
which it may be unethical to withhold treatment that is 
considered standard of care. 
ConClUsion
The treatment of PDPH in COVID-19 patients 
presents added risks and considerations. Specifically, 
the performance of an EBP in a COVID-19 patient may 
invite seeding of the COVID-19 virus into the CNS, in-
crease the CNS viral load, or both, the clinical implica-
tions of which, at this time, remain unknown. Previous 
studies of CNS infections after neuraxial procedures in 
patients with ongoing bacterial or viral infections point 
to an extremely low risk of seeding the CNS. Because of 
the paucity of information surrounding COVID-19 and 
its pathophysiology in the CNS, at this time we must 
rely on this evidence to guide our decision-making. 
We recommend caution before performing an EBP in 
a COVID-19 patient with PDPH. Initial treatment strate-
gies should consist of nonpharmacologic and pharma-
cologic treatment including the use of theophyllines 
and cosyntropin, although evidence for these remains 
insufficient. When appropriate, peripheral nerve blocks 
(GON or SPG) should also be considered before per-
forming an EBP. The evidence for the efficacy of these 
blocks is still limited but they generally present a very 
low risk (32). Going forward, an effective treatment for 
COVID-19 or a safe vaccine and a deeper understand-
ing of the pathophysiology of the virus will certainly 
change the risk calculus involved in performing an EBP 
in a COVID-19 patient.
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